ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 479

Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis

Evelyn Chow1, Isaac T. Cheng 1, Lai-Shan Tam 1 and CRYSTAL Study Team Hong Kong 2, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2The Chinese University of Hong Kong, Hong Kong

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Early Rheumatoid Arthritis, sustained remission and functional status

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Preventing functional loss is crucial to early RA (ERA) patients in order to maintain usual activities of daily living. However, whether achieving early and sustained remission could predict long-term functional status remain uncertain. The aim of this study is to ascertain whether early-sustained remission can prevent loss of functional ability in ERA patients.

Methods: ERA patients with symptom onset < 2 years were enrolled into the Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project. All subjects satisfied the 2010 ACR classification criteria for RA. Clinical assessments were performed for every three months in the first year, then yearly until the sixth year. Disease Activity Score 28 (DAS-28) and Health Assessment Questionnaire Disability Index (HAQ-DI) were recorded each visit. Early-sustained remission is defined as achieving DAS28-CRP < 2.6 consecutively from month 6 to year 4. Substantial functional ability loss is defined as HAQ-DI >0.5 at year 4. Potential independent predictors including baseline characteristics and early-sustained remission at year 4 were determined using multivariate logistic regression analysis.

Results: One-hundred-and-thirteen patients (age: 52.8±12.0 years, female: 90/113 (80%)) who completed year 4 assessment were included. Significant improvement in disease activity is observed (DAS28-CRP: 4.42±1.29 at baseline vs 2.34±0.99 at year 4, p< 0.001). Majority of patients (103/113, 91.2%) were on conventional synthetic DMARDs and 8/113 (7.1%) on biologic DMARDs. 47/113 (42%) patients achieved early-sustained remission, with 5/47 (11%) achieving drug-free remission. Patients with early sustained remission had a milder disease at baseline (Table 1). At year 4, there were less patients with substantial functional loss in the early-sustained remission group (6/46 (13%) vs 25/66 (40%), p=0.003) (Figure 1).

Using multivariate logistic regression, early-sustained remission is a protective factor for substantial functional loss at year 4 (OR: 0.26, 95% CI: 0.09-0.77, p=0.015) after adjusting baseline variables. Whereas independent risk factors for functional loss include female gender and HAQ-DI at baseline (Table 2).

Conclusion: Long-term functional ability loss can be prevented in ERA patients who achieved early-sustained remission. Baseline HAQ-DI indicates a risk factor for substantial functional loss, therefore early disease control aiming for consistent remission is crucial.

Figure 1. Proportion of patients with substantial functional ability loss at year 4

Table 1. Baseline characteristics

Table 2. Multivariate logistic regression


Disclosure: E. Chow, None; I. Cheng, None; L. Tam, None; C. Hong Kong, None.

To cite this abstract in AMA style:

Chow E, Cheng I, Tam L, Hong Kong C. Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/impact-of-achieving-early-sustained-remission-on-preventing-long-term-functional-loss-in-patients-with-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-achieving-early-sustained-remission-on-preventing-long-term-functional-loss-in-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology